About Burning Rock Biotech Ltd
Burning Rock Biotech (NASDAQ:BNR) specializes in precision oncology solutions, focusing on the development and commercialization of innovative cancer therapies. With a commitment to advancing cancer diagnosis and treatment, the company operates through a robust network of research, development, and clinical trial projects aiming to improve patient outcomes in the challenging landscape of oncology. Burning Rock's objectives include pushing the boundaries of personalized cancer care, enhancing the accuracy of tumor profiling, and expanding their portfolio of cancer detection tests. Their strategic approach involves collaborating with healthcare providers, leveraging advanced genomic analysis technologies, and fostering innovation to address unmet needs in cancer care, all while maintaining a patient-centered philosophy.
Snapshot
Operations
Products and/or services of Burning Rock Biotech Ltd
- Oncology precision medicine services, providing diagnostics and treatment guidance for cancer patients.
- Next-generation sequencing-based cancer therapy selection tests, aiding in personalized treatment plans.
- Comprehensive genomic profiling tests, helping to identify actionable mutations in various cancers.
- Research and development of cancer detection and monitoring solutions, focusing on early diagnosis.
- Collaboration with pharmaceutical companies for companion diagnostic developments, enhancing targeted therapy selection.
- Development of innovative cancer-related bioinformatics platforms, improving data analysis and interpretation for research and clinical applications.
Burning Rock Biotech Ltd executive team
- Mr. Yusheng HanFounder, Chairman & CEO
- Ms. Xiaozhi HuSenior Director of Finance
- Dr. Zhihong ZhangCTO & Director
- Mr. Hao LiuSenior Advisor
- Dr. Xinru MaoHead of Pharma Biomarker & CDx Service Head of International IVD Business